Why this ASX cannabis share is shooting 15% higher today

The Medlab Clinical Ltd (ASX:MDC) share price is shooting higher on Monday despite the market selloff. Here's why this cannabis share is on a high…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The market may be sinking lower again on Monday, but that hasn't stopped the Medlab Clinical Ltd (ASX: MDC) share price from charging higher.

The cannabis-focused biotech company's shares are up 15.5% to 26 cents in morning trade.

Why is the Medlab share price charging higher?

Investors have been buying Medlab's shares this morning following the release of an independent review of its NanaBis advanced cancer pain trial conducted at the Royal North Shore Hospital (RNSH).

The clinical trial was a Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) investigation into pain management of patients with metastatic cancers.

According to the release, the trial met its primary endpoints and found that NanaBis is tolerable, efficacious, fast acting, and delivered improvements in quality of life measures. This was particularly the case in role and emotional functioning and insomnia.

In addition to this, secondary endpoints were met. This includes a meaningful pain reduction and significantly less morphine milliequivalent of dispensed opioid analgesics prescribed for breast or prostate cancers with bone metastasis.

Management believes this was a robust trial that has delivered strong results and allows it to focus on Phase 3 designs.

Dr Sean Hall, CEO of Medlab, advised, "With a strong trial design, that involved a professional and strong clinical trial team and collaborators, today we have primary evidence that NanaBis is safe, tolerable and provided a significant benefit in managing pain associated with metastatic cancers."

"There were a number of notable secondary gains, one of the biggest worth mentioning was a drastic reduction of breakthrough medication used by those patients with breast or prostate cancers with bone METs."

Dr Hall concluded: "We can confidently argue, NanaBis has a strong indication for use in pain management and is a compelling therapy for this patient group."

It is still very early days, but there is a potentially big opportunity for the product if everything goes to plan. The company notes that metastatic breast or prostate cancers have a high unmet need, with conservative 2017 numbers suggesting 600,000 patients in USA, Canada, Europe, and Australia.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Share Gainers

Why Harvey Norman, Macquarie Technology, Ramsay Health Care, and Star are rising

These ASX shares are having a strong day. But why?

Read more »

A man looking at his laptop and thinking.
Share Gainers

Should I buy Nvidia stock as an Australian investor?

Many Aussies are thinking of jumping on the bandwagon, but they need to think about these issues first.

Read more »

A woman sits in a cafe wearing a polka dotted shirt and holding a latte in one hand while reading something on a laptop that is sitting on the table in front of her
Share Gainers

Here are the top 10 ASX 200 shares today

It was a rough day for ASX 200 investors this Wednesday.

Read more »

A woman's hair is blown back and her face is in shock at this big news.
Share Gainers

Why APM, DroneShield, EOS, and NextDC shares are charging higher

These ASX shares are having a strong session on Wednesday. But why?

Read more »

A happy businessman pointing up, inidicating a rise in share price
Materials Shares

Why are ASX lithium shares like Liontown having such a bumper session today?

Lithium shares are defying the broader market on Wednesday.

Read more »

Man with rocket wings which have flames coming out of them.
Share Gainers

This ASX All Ords stock just surged 88% in less than 3 days! Any guesses?

The ASX All Ords stock is drawing intense buying interest from investors this week.

Read more »

A little girl with red hair runs excitedly with a rocket strapped to her back, trying to launch.
Share Gainers

This small-cap ASX stock just rocketed 39%. What's doing?

A stock no one has heard of is lighting up trading screens on Wednesday. You might hear this name more…

Read more »

A man eases back onto his sofa, happy with the relaxed vibe from his furniture.
Share Gainers

If you'd put $30,000 in this ASX retail stock 11 months ago, you'd have $116,000 now

When battered stocks make a comeback, it happens very quickly. Here's a prime example.

Read more »